Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma

27 Sept 2017

Abstract excerpt

Abstract Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to bortezomib resistance. Specifically, we engineered an RPMI8226 multiple myeloma cell line to express Cas9 infected by lentiviral vector CRISPR library and cultured derived cells in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28958990
DOI: 10.1158/1535-7163.mct-17-0130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple MyelomaPMID 28958990Read ↗

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaSemantic proximity Read ↗

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple MyelomaSemantic proximity Read ↗

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myelomaSemantic proximity Read ↗

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaSemantic proximity Read ↗

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.Semantic proximity Read ↗

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

CRISPR-based screens uncover determinants of immunotherapy response in multiple myelomaSemantic proximity Read ↗

CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network.Semantic proximity Read ↗

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.